Progression Of Liver Fibrosis In Blood Donors Infected With Hepatitis C Virus

Background/Aims. Chronic hepatitis by HCV is progressive towards cirrhosis, with variable rate. We evaluated the rate of fibrosis progression (RFP), risk factors associated with advanced fibrosis (F3 and F4), and estimated the evolution time to cirrhosis. Methods. We transversely selected 142 blood donors infected only with HCV, with a known route of infection, submitted to liver biopsy at admission. RFP= ratio between stage of fibrosis (METAVIR)/estimated duration of infection in years. Non-parametric tests and logistic regression analysis, with significance level of 5% were used. Results. Median RFP was 0.086 U/year (0.05 - 0.142). Ten patients had F4 and 25 had F3. Median RFP values were significantly different (p=0.001) from one age group at contamination to the others and ALT and AST levels. There were no differences in the expected evolution to cirrhosis between intermediate fibrosers (F2) and the rapid fibrosers (F3 and F4). The independent variables associated with advanced fibrosis were ALT (OR 7.2) and GGT (OR 6.4) and age at inclusion (OR 1.12). Conclusion. This study suggests that RFP is extremely variable, it is exponential with age, and mainly influenced by host characteristics, especially age at contamination and possibly ethnical group. These asymptomatic patients had high percentage of fibrosis F2, F3 and F4.134291297Seeff, L.B., Natural history of hepatitis C (1997) Hepatology, 26 (SUPPL. 1), pp. S21-S28Alter, H.J., Seeff, L.B., Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome (2000) Semin Liver Dis, 20, pp. 17-35Di Bisceglie, A.M., Hepatitis C and hepatocellular carcinoma (1997) Hepatology, 26 (SUPPL. 1), pp. S34-S38EASL: International consensus conference on hepatitis C. Consensus statement (1999) J Hepatol, 30, pp. 956-961Fattovich, G., Giustina, G., Degos, F., Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients (1997) Gastroenterology, 112, pp. 463-472Serfaty, L., Aumaitre, H., Chazouilleres, O., Determinants of outcome of compensated hepatitis C virus-related cirrhosis (1998) Hepatology, 27, pp. 1435-1440Hu, K.-Q., Tong, M.J., The long-term outcomes of patients with compensated hepatitis C virus related cirrhosis and history of parenteral exposure in the United States (1999) Hepatology, 29, pp. 1311-1316Poynard, T., Bedossa, P., Opolon, P., Natural history of liver fibrosis progression in patients with chronic hepatitis C (1997) Lancet, 349, pp. 825-832Freeman, A.J., Dore, G.J., Law, M.G., Estimating progression to cirrhosis in chronic hepatitis C virus infection (2001) Hepatology, 34, pp. 809-816Poynard, T., Ratziu, V., Benmanov, Y., DiMartino, V., Bedossa, P., Opolon, P., Fibrosis in the patients with chronic hepatitis C, detection and significance (2000) Semin Liver Dis, 20, pp. 47-55Shivakumar, C., Jacob, G., Predictors of liver-related complications in patients with chronic hepatitis C (2000) Ann Med, 32, pp. 588-591Stuyver, L., Wyseur, A., Van Arnhem, W., Hernandez, F., Maertens, G., Second generation line probe assay for hepatitis C virus genotyping (1996) J Clin Microbiol, 34, pp. 2259-2266Silva, G.F., Nishimura, N.F., Caramori, C., Soares, E.C., Influence of a regional habit on the hepatitis C virus infection: The role of Gluconergan® (2001) Hepatology, 34, pp. 574ASeeff, L.B., Hollinger, F.B., Alter, H.J., Long-term mortality and morbidity of transfusion-associated Non-A, Non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute Collaborative study (2001) Hepatology, 33, pp. 455-463Seeff, L.B., Natural history of chronic hepatitis C (2002) Hepatology, 36, pp. S35-S46Sobesky, R., Mathurin, P., Charlotte, F., Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view (1999) Gastroenterology, 116, pp. 378-386Berenguer, M., Ferrel, L., Watson, J., HCV-related fibrosis progression following liver transplantation: Increase in recent years (2000) J Hepatol, 32, pp. 673-684Tanaka, E., Kiyosawa, K., Natural history of acute hepatitis C (2000) J Gastroenterol Hepatol, 15 (SUPPL.), pp. E97-E104Poynard, T., McHutchison, J., Manns, M., Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C (2002) Gastroenterology, 122, pp. 1303-1313Kim, W., Gross Jr., J.B., Poterucha, J.J., Locke, G.R., Dickson, R., Outcome of hospital care of liver disease associated with hepatitis C in the United States (2001) Hepatology, 33, pp. 201-206Ostapowicz, G., Watson, K.J., Locarnini, S.A., Desmond, P.V., Role of alcohol in the progression of liver disease caused by hepatitis C virus infection (1998) Hepatology, 27, pp. 1730-1735Bonacini, M., Groshen, S., Yu, M.C., Govindarajan, S., Lindsay, K.L., Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County (2001) Am J Gastroenterol, 96, pp. 2438-2441Khan, M.H., Farrell, G.C., Byth, K., Which patients with hepatitis C develop liver complications? (2000) Hepatology, 31, pp. 513-520Kage, M., Shimamatu, K., Nakashima, E., Kojiro, M., Inoue, O., Yano, M., Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: Morphometric analysis of repeated biopsies (1997) Hepatology, 25, pp. 1028-1031Matsumura, H., Moriyama, M., Goto, I., Tanaka Nokubo, H., Arakawa, Y., Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C: A study of 527 patients at one stablishment (2000) J Viral Hepat, 7, pp. 268-275Adinolfi, L.E., Gambardella, M., Andreana, A., Tripodi, M.F., Utili, R., Ruggiero, G., Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity (2001) Hepatology, 33, pp. 1358-1364Monto, A., Alonzo, J., Watson, J.J., Grunfeld, C., Wright, T.L., Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol (2002) Hepatology, 36, pp. 729-736Mathurin, P., Moussalli, J., Cadranel, J.F., Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity (1998) Hepatology, 27, pp. 868-872Jamal, M.M., Soni, A., Quinn, P.G., Wheeler, D.E., Arora, S., Johnston, D.E., Clinical features of hepatitis C infected patients with persistently normal alanine transaminase levels in the southwestern United States (1999) Hepatology, 30, pp. 1307-1311Hervé, S., Savoye, G., Riachi, G., Chronic hepatitis C with normal or abnormal aminotransferase levels: Is it the same entity? (2001) Eur J Gastroenterol Hepatol, 13, pp. 495-500Poynard, T., Ratziu, V., Charlotte, F., Goodman, Z., McHutchison, J., Albrecht, J., Rates and risk factors of liver fibrosis progression in patients, with chronic hepatitis C (2001) J Hepatol, 3